We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
Add this topic to your myFT Digest for news straight to your inbox
Swiss drugmaker’s generic business could have market capitalisation of $18bn-$25bn
Pharma industry deprioritising certain pills with shorter exclusivity period, says head of Swiss drugmaker
Swiss drugmaker says potential deals not attractive enough to pursue
Vas Narasimhan warns giving Brussels power over drug manufacturing during crises will hit investment
Swiss group rethinks NHS collaboration after low take-up of treatment during rollout via GPs
Technology has the potential to forge closer relationships between law firms and clients
Swiss group takes bold step to focus on faster-growing and higher-margin medicines
Chief executive says changes will make Swiss drugmaker ‘more agile and competitive’
The Swiss company’s chief executive has to decide on the future of its $10bn generics business
Potential suitors include Blackstone and Carlyle but no formal bids have been made
Selling off its Sandoz unit could help stave off an attack by activists
Blackstone, Carlyle and EQT among those interested in bidding for drug manufacturer Sandoz
Swiss drugmaker to license antiviral therapeutic after success in early-stage tests
Twenty-year shareholding had kept the two Swiss drugmakers closely linked
‘Pure pharma’ companies were the minority a decade ago but are now back in fashion
Unit accounts for a fifth of group sales and could be spun off
Health service to target use of Novartis drug inclisiran in bid to prevent cardiovascular disease in England
Trial results for new targeted therapy ‘pretty remarkable’, says CEO
Swiss drugmaker says backlog reflects stretched healthcare systems and patient reluctance to visit doctors for screenings
Rome’s talks with manufacturers come as EU seems to be moving away from AstraZeneca and J&J
The pharmaceuticals are battling in similar markets, but their share price performances have diverged
Pharmaceutical company legal teams had to act quickly on Covid-related problem-solving
German group’s treatment is among only 9 candidates to have entered a phase 3 trial
Pharma group was accused of paying bribes to doctors and improperly funding drug purchases
Pandemic shows purpose can defy sceptics. Plus: six general counsel who stand out on sustainability
UK Edition
